Advance the Representation of African Americans in Clinical Trials

Learn About:

Strategies to address African American patients in clinical trials
How to implement evidence-based strategies

Expert Faculty Presenters:


	Heidi Crayton, MD Clinical Neurologist MS Center of Greater Washington Click here for biography

	Jacqueline Faulkner Rosenthal, MD Clinical Neurologist Andrew C. Carlos Multiple Sclerosis Institute Shepherd Center, Atlanta Click here for biography

	Victoria Reese Co-Founder and CEO We Are ILL Click here for biography

Target Audience
This initiative is intended for neurologists, MS subspecialists, primary care clinicians, ER providers, registered nurses, pharmacists, social workers, case managers, and other health care professionals involved in the treatment and management of Black patients with MS.

Statement of Need/Program Overview
The African American population is underrepresented in clinical trials today. This program will look at evidence-based strategies for health care providers to shift this current paradigm and will address some obstacles that impact minority participation in MS clinical trials.

Educational Objectives
After completing this activity, the participant should be better able to:

Apply strategies to address the underrepresentation of African Americans in MS clinical trials
Implement evidence-based strategies that will have a meaningful impact on the African American MS community

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine (PIM), the Multiple Sclerosis Association of America (MSAA) and Impact Education, LLC. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

UAN: JA4008162-9999-22-319-L01-P
Type of Activity: Knowledge

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Working Group Members/Planners*	*Reported Financial Relationship*
Heidi Crayton, MD	Consultant/Advisory Board: Biogen; Sanofi; EMD Serono; Janssen; Bristol Myers Squibb; Novartis Fees for Non-CE Services: Biogen; Sanofi; EMD Serono; Janssen; Bristol Myers Squibb Contracted Research: Biogen, Sanofi, EMD Serono, Atara, Anokion, Novartis
Jacqueline Faulkner Rosenthal, MD	Consultant/Advisory Board: Horizon, TG, EMD Serono, Alexion, Genentech
Victoria Reese	No financial interest/relationships relating to the topic of this activity

The PIM planners and managers have nothing to disclose.
The MSAA planners and managers have nothing to disclose.
The Impact Education, LLC^® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.